NCT02866136

Conservative Treatments of Retinoblastoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 133 (estimated)
• Sponsor: Institut Curie · Academic / Other
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

Conservative treatments of retinoblastoma (RETINO 2011) 1. -Multicentric non randomised, phase II study for the patients treated by chemoreduction (VP16, carboplatin) followed by chemothermotherapy without laser treatment at day 8 2. -Multicentric non randomised, phase II study for the patients with bilateral very asymmetric dis-ease (Group D eye on one of the eye) or unilateral presentation groups B/C/D according to the age and vitreous seeding 3. \- Multicentric non randomised, phase II study for the patients treated by 6 cycles of three drugs regimen and local treatments for bilateral group D eyes or on the only eye.

Conditions

• Retinoblastoma
• Children
• Retinal Neoplasm

Interventions

Type	Name	Description
DRUG	VP16, carboplatin	Systemic treatment : Intravenous injections, 2 cycles (21 days)
DRUG	Melphalan	intraarterial injections, 3 to 6 cycles (1 month)
DRUG	VP16, carboplatin, vincristin	Systemic treatment : Intravenous injections, 6 cycles (21 days)
DRUG	Carboplatin + laser day 1 (chemothermotherapy)	Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
DEVICE	Laser (local treatment)
DEVICE	cryoapplication (local treatment)
RADIATION	I125 radioactive plaques (local treatment)
DRUG	intravitreal Melphalan (local treatment)

Timeline

• Start date: 2012-02-01
• Primary completion: 2023-01-01
• Completion: 2035-09-01
• First posted: 2016-08-15
• Last updated: 2025-11-24

Locations

1 site across 1 country: France